Skip to Main Content

Paper Details

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.
Drugs Context
1
2022
CA15, CDK4/6, CEA, PD, advanced breast cancer, cancer antigen 15, carcinoembryonic antigen, metastatic breast cancer, patients, tumour
Author NameAffiliation
Alberto MaloviniLaboratory of Informatics and Systems Engineering for Clinical Research, IRCCS-ICS Maugeri
Alberto MaloviniLaboratory of Informatics and Systems Engineering for Clinical Research, IRCCS-ICS Maugeri
  • 1 - 2

Datasets

Release 1.2